Scholar Rock Wins First FDA Approval for Rare Muscle-Wasting Disease
The U.S. Food and Drug Administration approved Scholar Rock’s injectable treatment Isembyld on Sept. 11 to improve motor function in adults and children with spinal muscular atrophy, marking the company’s first regulatory approval and sending shares up over 23% in after-market trading, according to Reuters. FDA Grants First Regulatory Approval to Scholar Rock for Isembyld … Read more
